Genetic effects on treatment response of umeclidinium/vilanterol in chronic obstructive pulmonary disease

Treatment with long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) for chronic obstructive pulmonary disease (COPD) is standard, but response varies. We investigated genetic association with treatment response to umeclidinium (UMEC, a LAMA), vilanterol (VI, a LABA), and combination therapy.

Source: Respiratory Medicine CME - March 30, 2016 Category: Respiratory Medicine Authors: Lynn Condreay, Lingkang Huang, Elizabeth Harris, Jean Brooks, John H. Riley, Alison Church, Soumitra Ghosh Tags: Short communication Source Type: research